MALT lymphoma · 3 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Chlorambucil and Rituximab (RClb) Variant #01 | — | R 52 650 | 42d | — | — | ~6 | ~R 160 474 PFS proxy · indirect | 1 |
Chlorambucil monotherapy Variant #03 | — | R 2 355 | 28d | ~12.6 mo | ~69.7 mo | ~13 | ~R 30 610 PFS proxy · indirect | 6 |
Observation Partial | — | — | — | ~25.4 mo | — | — | — | 8 |
3 of 3 regimens shown